Cambridge Healthtech Institute’s Fourth Annual
Antibodies for Cancer Therapy
Exploiting Successful Strategies
Part of the Tenth Annual PEGS: the essential protein engineering summit
May 5-6, 2014| Seaport World Trade Center | Boston, MA
This conference will focus on the current status of therapeutic antibodies and on the outlook for the future. This year’s agenda will highlight diverse topics such as identifying and validating novel targets, optimizing drug-like properties, increasing tumor penetration, employing novel constructs, and regulating novel therapeutic antibodies. Additionally, emphasis will be placed on learning from molecules in clinical development. We will review the vibrant community of therapeutic antibodies and discover the latest trends for future best-in-class drugs.
Harnessing the Patient’s Immune System to Combat Cancer
Bahija Jallal, Ph.D., Executive Vice President, MedImmune
Building One of the World’s Top Biotechnology Companies from the Ground Up: The Story of Regeneron
George D. Yancopoulos, M.D., Ph.D., President, Regeneron Laboratories; CSO, Regeneron Pharmaceuticals, Inc.
Discovering Novel Antibody Targets in the Golden Age of Antibody Therapeutics
Elizabeth M. Jaffee, M.D., The Dana & Albert “Cubby” Broccoli Professor, Oncology; Co-Director, Gastrointestinal Cancers Program; Associate Director, Translational Research, Johns Hopkins University
Recent Advances in Cancer Immunotherapy
Michael B. Atkins, M.D., Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center; Professor, Oncology and Medicine, Georgetown University Medical Center
Glass Half-Empty or Half-Full? Potential Mechanisms of Non-Response to Immunomodulatory Antibodies
Robert Pierce, M.D., Executive Director, Pathology, MRL-Palo Alto, Merck
Mechanisms by which Tumor Antigen-Specific Antibodies Enhance and Skew Tumor Antigen-Specific Cellular Immune Responses
Robert L. Ferris, M.D., Ph.D., UPMC Chair, Advanced Oncologic Head and Neck Surgery; Associate Director, Translational Research; Co-Leader, Cancer Immunology Program, University of Pittsburgh Cancer Institute
Gordon Freeman, Ph.D., Associate Professor, Medicine, Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
Therapeutic Antibodies Targeting Glypican-3 in
Mitchell Ho, Ph.D., Chief, Antibody Therapy Section, Laboratory of Molecular Biology, National Cancer Institute, NIH
Evaluation of T Cell Agonists for Cancer Immunotherapy
Jeong Kim, Ph.D., Scientist, Cancer Immunotherapy, Genentech, Inc.
Antibodies Targeting Signaling Pathways
Timothy Hoey, Ph.D., Senior Vice President, Cancer Biology, OncoMed Pharmaceuticals, Inc.
BNC101: A Highly Selective, Humanized Antibody Targeting LGR5 on Cancer Stem Cells
Christopher L. Reyes, Ph.D., Vice President, Research & Development Biologics, Bionomics, Inc.
Tumor Antigen-Specific Antibody-Based Immunotherapy of Malignant Disease, Cancer Initiating Cells and Disease Recurrence
Soldano Ferrone, M.D., Ph.D., Lecturer, Surgical Oncology, Surgery, Massachusetts General Hospital
Using Peptide Conjugation to Create Brain-Penetrant mAbs for Targeting Metastatic Brain Tumors
Jean Lachowicz, Ph.D., CSO, R&D, Angiochem
Talk Title to be Announced
Horacio G. Nastri, Ph.D., Director, Biotherapeutics, Center for Therapeutic Innovation (CTI), Pfizer, Inc.
Discovery and Development of GAZYVA (obinutuzumab, GA101): A Glycoengineered Type II CD20 Antibody for the Therapy of Chronic Lympocytic Leukemia
Christian Klein, Ph.D., Discovery Oncology oDTA, Pharma Research and Early Development (pRED), Roche Glycart AG
Trastuzumab Induces Phosphorylation of EGFR Family Receptors to Mediate CSK-Homologous Kinase-Coupled Growth Inhibitory Pathway
Wen Jin Wu, M.D., Ph.D., Senior Investigator, Monoclonal Antibodies, Office of Biotechnology Products, Office of Pharmaceutical Science, Center for Drug Evaluation and Research, FDA